Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01173809 · ClinicalTrials.gov registry record · Phase 3

Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation

A Phase 3 study of Atrial Fibrillation, sponsored by Texas Cardiac Arrhythmia Research Foundation.

Completed
Registry status
Phase 3
Development phase
176
Enrollment target
1
Study location

NCT01173809 is a Phase 3 study of Atrial Fibrillation that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 176 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01173809, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.

COMPLETED
Registry status
Phase 3
Development phase
176 participants
Enrollment target
1
Study location

Study Summary

This prospective randomized study aims to investigate the effect of continuous versus interrupted use of Amiodarone on the procedure outcome in long-standing persistent (LSP) atrial fibrillation patients undergoing pulmonary vein antral isolation (PVAI).

Conditions Studied

Interventions

  • DRUG Amiodarone

Study Locations (1)

Texas

  • St.David's Medical Center - Austin

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2010-10
Est. Completion 2014-07
Phase Phase 3

What the Registry Record Tells You About NCT01173809

The ClinicalTrials.gov registry entry for NCT01173809 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The listed sponsor is Texas Cardiac Arrhythmia Research Foundation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Amiodarone is the first listed.

NCT01173809 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01173809 about?

NCT01173809 is a clinical study titled "Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation". This prospective randomized study aims to investigate the effect of continuous versus interrupted use of Amiodarone on the procedure outcome in long-standing persistent (LSP) atrial fibrillation patients undergoing pulmonary vein antral isolation (PVAI).

What is the current status of trial NCT01173809?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2010-10. Estimated completion is 2014-07.

What conditions does trial NCT01173809 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT01173809?

The interventions under investigation include: Amiodarone (DRUG).

Who is sponsoring clinical trial NCT01173809?

This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01173809 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.